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Abstract
Background: In a number of drug and psychotherapy comparative trials, psychotherapy-placebo
combination has been assumed to represent psychotherapy. Whether psychotherapy plus pill
placebo is the same as psychotherapy alone is an empirical question which however has to date
never been examined systematically.
Methods: We conducted a systematic review and meta-analysis of randomised controlled trials
(RCTs) that directly compared cognitive-behavior therapy (CBT) alone against CBT plus pill
placebo in the treatment of panic disorder.
Results: Extensive literature search was able to identify three relevant RCTs. At the end of the
acute phase treatment, patients who received CBT plus placebo had 26% (95%CI: 2 to 55%)
increased chances of responding than those who received CBT alone. At follow-up the difference
was no longer statistically significant (22%, 95%CI: -10% to 64%).
Conclusion: The act of taking a pill placebo may enhance the placebo effect already contained in
the effective psychotherapeutic intervention during the acute phase treatment. Theoretically this
is an argument against the recently claimed null hypothesis of placebo effect in general and clinically
it may point to some further room for enhancing the psychotherapeutic approach for panic
disorder.
Background
The observed treatment effect, i.e. the change from base-
line till endpoint, is traditionally thought to be due to
four factors: regression towards the mean, natural course
of disease, placebo effect i.e. non-specific effects of the
therapist and the setting in which therapy takes place, and
specific effects of physical or psychological intervention
on the target condition [1].
When a specific therapy for a certain disorder exists, we
therefore assume that it realizes all these four components
through its administration. Cognitive-behavior therapy
(CBT) for panic disorder is one such instance, because it
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has demonstrated its superiority in the rigorously inter-
nally calibrated, drug-sensitive [2] group of patients vis-à-
vis the pill placebo arm [3] and also against a non-specific
psychological intervention [4].
Whether adding pill-placebo to specific psychotherapy
enhances its effectiveness is an empirically and theoreti-
cally interesting question [5]. Some may assume that a
specifically effective treatment has already realized all the
above-mentioned four components of treatment effect
and therefore addition of a pill placebo cannot enhance
its effect. On the other hand, some may suspect that addi-
tion of pill placebo may subtract from psychological treat-
ment because it may undermine the active commitment
of the patient to follow psychological interventions. Or,
some may argue that psychotherapy placebo and pharma-
cotherapy placebo work through different psychological
mechanisms and can therefore be additive or synergistic.
While conducting a comprehensive systematic review of
randomized controlled trials (RCT) of the combined psy-
chological and drug treatment for panic disorder [6,7], we
had a unique opportunity to compare the psychotherapy
alone versus the psychotherapy plus pill placebo arms and
would like to repot the results.
Methods
Identification of trials
In order to identify all randomized controlled trials that
compared psychotherapy against psychotherapy plus pla-
cebo, we looked for all trials that examined the combina-
tion of psychotherapy and pharmacotherapy by
antidepressant or benzodiazepines, two types of drugs
known to be effective for panic disorder.
Both individual and group formats of the following psy-
chological treatments were included: behavior therapy
involving some kind of exposure, cognitive therapy which
uses some kind of cognitive restructuring, cognitive-
behavior therapy involving elements of both cognitive
and behavioral therapies, and other psychological inter-
ventions. All commonly prescribed antidepressants and
benzodiazepines were eligible.
We electronically searched the Cochrane Collaboration
Depression, Anxiety and Neurosis Controlled Trials Regis-
ter (CCDANCTR) with keywords antidepressant OR benzo-
diazepines and panic in April 2003 and October 2005. The
CCDANCTR is a study-based register of randomized trials
incorporating results of group searches of MEDLINE
(1966-), EMBASE (1980-), CINAHL (1982-), PsycINFO
(1974-), PSYNDEX (1977-) and LILACS (1982–1999)
and handsearches of major psychiatric and medical jour-
nals. Two complementary searches for additional relevant
trials were conducted with the Cochrane Central Register
of Controlled Trials (CENTRAL) and with MEDLINE. No
language restriction was imposed.
Two reviewers examined titles and abstracts of studies
identified by the electronic search strategies and then
checked full articles for eligibility. To identify further tri-
als, references of these selected studies and of other review
papers were also checked, representative studies were sub-
jected to SciSearch, and experts were contacted.
Quality assessment and data extraction
Two independent reviewers (NW and TAF) assessed the
methodological quality of the selected studies. The criteria
for quality assessment were based on recommendations
in the Cochrane Handbook for Systematic Reviews of
Interventions [8], which focused on the quality of alloca-
tion concealment. We also rated whether at least one out-
come measure was assessed by an independent assessor
blind to treatment allocation.
Two reviewers independently extracted data from the orig-
inal reports using data extraction forms. For studies where
exact numbers of responders were not presented but only
their means and standard deviations (SDs) of the global
severity measure, we imputed response rates by using a
validated imputation method [9] in order to conduct
intention-to-treat (ITT) analyses as described below. Any
disagreement was resolved by consensus between the first
three reviewers.
Data synthesis
Our primary outcome was "response," i.e. substantial
improvement from baseline as defined by the original
investigators. Examples would be "very much or much
improved" according to the Clinical Global Impression
Change Scale [10], and more than 40% reduction in the
Panic Disorder Severity Scale [11] score or in panic fre-
quency. The total number of dropouts for any reason was
regarded as a proxy measure of treatment acceptability.
Adverse effects were evaluated by looking at the number
of dropouts due to adverse effects.
For dichotomous outcomes, ITT analysis was adopted.
When dropouts were excluded from any assessment in the
primary studies (for example, those who never returned
for assessment after randomization), they were consid-
ered non-responders. Relative risks (RR) and their 95%
confidence intervals were calculated using random effects
model rather than a fixed effects model because of its gen-
eralizability [12].
Heterogeneity, which refers to variability among studies
in a systematic review and generally derives from clinical,
methodological or statistical diversity [8], was assessed by
Chi-squared statistics and I-squared statistics [13].BMC Psychiatry 2007, 7:73 http://www.biomedcentral.com/1471-244X/7/73
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Results
Description of studies
The electronic search identified 274 studies from
CCDANCTR, 231 from CENTRAL and 35 from MEDLINE.
Browsing their titles and abstracts, 195 articles were iden-
tified by either of the two independent reviewers as possi-
ble candidates and their full copies were obtained. With
further reference search, SciSearch and personal contacts,
we identified 25 studies that examined the combination
of psychotherapy plus pharmacotherapy for panic disor-
der. Of these, three studies included psychotherapy plus
placebo as well as psychotherapy alone arms: Barlow et
al.[3], de Beurs et al.[14], and Sharp et al.[15]. Table 1
gives details of the participants' characteristics, the inter-
ventions, and the definition of response in these three tri-
als. All three trials examined behavioral and cognitive
therapies and in the following we summatively refer to
them as CBT.
Acute phase treatment
At the end of the acute phase treatment which lasted 12
weeks in all the three trials, patients who received CBT
plus placebo were 1.26 (95%CI: 1.02 to 1.55) times more
likely to show response than those who received CBT
alone (Figure 1). There was no statistical heterogeneity
among the three trials.
Treatment acceptability, as measured by the total number
of dropouts for any reasons, did not differ between the
two groups (RR = 0.83, 0.40 to 1.72). There were no drop-
outs due to side effects in psychotherapy alone or psycho-
therapy plus placebo arms of the three trials.
Follow-up after trial termination
At follow-up 6 to 24 months after termination of the tri-
als, psychotherapy plus placebo was no longer statistically
significantly superior to psychotherapy alone (RR = 1.22,
0.90 to 1.64). The I-squared statistic was 0%, indicating
no heterogeneity in the pooled results (Figure 2).
Discussion
The present report represents the first systematic empirical
examination of the effect of adding pill placebo to psycho-
therapy. It found that, for panic disorder with or without
agoraphobia, pill placebo may enhance CBT during the
acute phase treatment. There was no difference in treat-
ment acceptability between these two treatment arms. The
difference in effectiveness, however, seemed to wane in
6–24 months after end of the acute phase treatment.
Twenty-five years ago, Hollon and DeRubeis argued that
placebo-psychotherapy combination cannot represent
psychotherapy in drug-psychotherapy comparative trials
but could not determine from the literature review then
whether the former would overestimate or underestimate
the latter [5]. The current study has assembled newer data
and suggests that placebo-psychotherapy combination
overestimates the latter and that therefore Hollon and
DeRubeis's concerns proved justified.
Table 1: Characteristics of the included studies
Study Participants Interventions Outcomes
Barlow et al (2000) DIAGNOSIS: DSM-III-R panic disorder 
with mild to no agoraphobia
AGE: mean = 34.1 to 37.8 years
SEX: 62% women
12 weeks of:
1. imipramine (mean = 214 to 239 mg/d 
by week 12) + CBT (11 sessions during 3 
months)
2. imipramine alone
3. CBT alone
4. CBT + placebo
5. placebo alone
RESPONSE: > = 40% reduction 
on PDSS
De Beurs et al (1995) DIAGNOSIS: DSM-III-R panic disorder 
with moderate to severe agoraphobia
AGE: mean = 38.8
SEX: 75% women
12 weeks of:
1. fluvoxamine (100–150 mg/day) + 
exposure (12 weekly sessions)
2. exposure alone
3. placebo + exposure
4. psychological panic management plus 
exposure
RESPONSE: > = 40% reduction 
in panic frequency [imputed 
from its mean & SD]
Sharp et al (1996) DIAGNOSIS: DSM-III-R panic disorder 
with or without agoraphobia (% 
agoraphobia unclear; however, the 
average score for FQ-Ag was around 15, 
indicating most had at least some 
agoraphobia)
AGE: mean = 33.2 to 38.8
SEX: 78% women
12 weeks of:
1. fluvoxamine (100–150 mg/day) + CBT 
(12 sessions)
2. fluvoxamine alone
3. CBT alone
4. CBT + placebo
5. placebo alone
RESPONSE: "Very much" or 
"Much improved" on CGI 
Change
PDSS: Panic Disorder Severity Scale, CGI: Clinical Global ImpressionBMC Psychiatry 2007, 7:73 http://www.biomedcentral.com/1471-244X/7/73
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The fact that pill placebo can add to psychotherapy is
intriguing. Theoretical implications of the present find-
ings may be two. Firstly, in contrast to some old claims
[16], taking a pill placebo did not undermine the effec-
tiveness of psychological intervention. Secondly, much to
the contrary, pill placebo enhanced the effectiveness of
CBT. The act of taking an inactive drug can enhance the
placebo effect already contained in the effective psycho-
therapeutic intervention. This is a strong argument against
the recently claimed null hypothesis of placebo effect
[17].
The observed pill placebo effect over and above the
proven psychotherapy may be explainable from both of
the main theoretical models of the placebo effect, namely
the classical conditioning [18] and expectancy theory [19]
In the life of a modern man the beneficial experience of a
pill is almost inescapable and this may have contributed
to the placebo effect through pill taking in addition to the
same through talk therapy. In other words, the pill has
become a conditioned stimulus, eliciting a conditioned
response which is placebo effect. Or alternatively, accord-
ing to the expectancy theory, patients expect more from
pill and talk therapy so that they respond more to pill and
talk therapy. The fact that the benefit of the pill placebo
appeared to wane after the treatment termination is com-
patible with both of these theoretical models. In fact,
although they are often presented as competing perspec-
tives, the two theories are not necessarily incompatible
with each other [20].
Pragmatic implications of the present findings may not be
as straightforward. We have formerly established that
antidepressant drug plus CBT was more effective than pla-
cebo plus CBT at the end of the acute phase treatment [6].
It appears that psychotherapy plus pill placebo would
come in-between the two, but in clinical practice prescrib-
ing a pill placebo will be very difficult if not unethical. It
is important to note, however, that there is some further
room to enhance placebo effect when administering CBT
to panic disorder.
There are some possible weaknesses to the present study.
In the first place, despite our intensive and extensive liter-
ature search, we were able to identify only three trials that
made a head-to-head comparison between psychotherapy
plus placebo against psychotherapy alone. The present
findings therefore may lack statistical power and should
be regarded exploratory and preliminary. Secondly, in two
of the three included studies, the primary outcomes were
Response on CBT + placebo vs CBT alone in the acute phase treatment Figure 1
Response on CBT + placebo vs CBT alone in the acute phase treatment.
Study  CBT+placebo
or sub-category  n/N
 CBT alone  RR (random)  Weight  RR (random)
 n/N  95% CI  %  95% CI
 Barlow 2000                36/63              37/77          43.28      1.19 [0.87, 1.63]        
  8.20      1.50 [0.73, 3.10]          de Beurs 1995              12/24               7/21        
 Sharp 1996                 28/36              26/43          48.52      1.29 [0.95, 1.73]        
100.00      1.26 [1.02, 1.55] Total (95% CI) 123                141
Total events: 76 (CBT+placebo), 70 (CBT alone)
Test for heterogeneity: Chi² = 0.37, df = 2 (P = 0.83), I² = 0%
Test for overall effect: Z = 2.17 (P = 0.03)
 0.2  0.5  1  2  5
 Favours CBT alone  Favours CBT+placebo
Response on CBT + placebo vs CBT alone at 6–24 months after acute phase treatment Figure 2
Response on CBT + placebo vs CBT alone at 6–24 months after acute phase treatment.
Study  CBT+placebo
or sub-category  n/N
 CBT alone  RR (random)  Weight  RR (random)
 n/N  95% CI  %  95% CI
 Barlow 2000                25/62              24/73          44.50     1.23 [0.78, 1.92]       
 24.53     1.05 [0.58, 1.92]         de Beurs 1995              12/24              10/21        
 Sharp 1996                 17/36              15/43          30.98     1.35 [0.79, 2.31]       
100.00      1.22 [0.90, 1.64] Total (95% CI) 122                137
Total events: 54 (CBT+placebo), 49 (CBT alone)
Test for heterogeneity: Chi² = 0.39, df = 2 (P = 0.82), I² = 0%
Test for overall effect: Z = 1.29 (P = 0.20)
 0.2  0.5  1  2  5
 Favours CBT alone  Favours CBT+placeboBMC Psychiatry 2007, 7:73 http://www.biomedcentral.com/1471-244X/7/73
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rated by raters who were not blind to the psychotherapy
status but who were blind only to the drug status (active
drug vs placebo). However, we must note that the abso-
lute degree of heterogeneity, as expressed by I-squared val-
ues and as visually observable in forest plots (Figures 1
and 2), was close to zero among the one blind and two
non-blind studies. The open nature of the assessment can
therefore not explain away the observed difference.
Thirdly, the response rate had to be imputed in one of the
three studies [14] based on the panic frequency, which
likely not reflect the whole panic disorder psychopathol-
ogy. Deleting this study, however, did not affect the out-
comes (RR = 1.24, 95%CI: 1.00 to 1.54 at the end of acute
phase treatment, and RR = 1.28, 95%CI: 0.91 to 1.80 at
6–24 months after treatment discontinuation). We were
also unable to conduct detailed meta-analyses of continu-
ous variables presented in the identified studies because
each rated some different aspects of panic disorder. For
example, one RCT reported frequency of panic attacks,
two reported on phobic avoidance, two reported on gen-
eral anxiety, one reported depression and one reported
social dysfunction on various continuous scales. The field
would certainly benefit from wider-spread use of a more
common metric of overall panic disorder severity, such as
the Panic Disorder Severity Scale [11]. Lastly, our results
concern panic disorder only and generalizability beyond
this disorder is not guaranteed. More systematic reviews
on this topic in other disorders are warranted.
Conclusion
The act of taking a pill placebo may enhance the placebo
effect already contained in the effective psychotherapeutic
intervention during the acute phase treatment. There may
be some further room for enhancing the psychotherapeu-
tic approach for panic disorder.
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